Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Metformin Hydrochloride; Repaglinide Patent Expiration

Metformin Hydrochloride; Repaglinide is used for managing blood glucose levels in patients with diabetes. It was first introduced by Novo Nordisk Inc in its drug Prandimet on Jun 23, 2008. 2 different companies have introduced drugs containing Metformin Hydrochloride; Repaglinide.


Metformin Hydrochloride; Repaglinide Patents

Given below is the list of patents protecting Metformin Hydrochloride; Repaglinide, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Country : United States (US)
Patent Category : All
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Prandimet US6677358 NIDDM regimen Jun 12, 2018

(Expired)

 Novo Nordisk Inc



Metformin Hydrochloride; Repaglinide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Metformin Hydrochloride; Repaglinide Generic API Manufacturers

Several generic applications have been filed for Metformin Hydrochloride; Repaglinide.

Given below is the list of companies who have filed for Metformin Hydrochloride; Repaglinide generic, along with the locations of their manufacturing plants worldwide.